David Benito Laorga’s Haemophilia Team Hosts Hemosfera
David Benito Laorga, Business Unit Director and Management Team Member Novo Nordisk Spanish Affiliate, shared on LinkedIn:
”This weekend, our haemophilia team hosted Hemosfera, a truly innovative meeting centered on a new treatment with the potential to reduce treatment burden, improve quality of life, and open new possibilities for patients and families.
I’m especially proud of the team behind the scenes.
From concept to execution, this event was powered by strong ownership, deep commitment, and a shared conviction that meaningful innovation requires doing things differently—and doing them well.
This is what high-performing teams look like.
My sincere thanks as well to all the speakers for the depth and quality of the discussions.
Your insights and engagement were critical to making this a truly valuable and impactful event.
Proud of the team. Motivated by the impact we can create for patients.”
Stay updated with Hemostasis Today.
-
Mar 16, 2026, 17:42Mohamed Sherif Salem: Turning 2026 KDIGO Complexity into Bedside Clarity
-
Mar 16, 2026, 17:39Julie Cardoso: What Happens to Venous Valves When a Blood Clot Forms?
-
Mar 16, 2026, 17:38Nasir Jamal: Blood Transfusion Criteria and Hemodialysis Thresholds in ESRD Patients
-
Mar 16, 2026, 17:37Octavio Cosín Sales: Understanding the Influence of Systemic Factors on Chronic Venous Insufficiency
-
Mar 16, 2026, 17:35Shiny K. Kajal: From Simple Calcium Chelation to Full-Blown Red Cell Metabolic Engineering
-
Mar 16, 2026, 17:12Cold-Stored vs Room-Temperature Platelets in Trauma-Induced Coagulopathy – JTH
-
Mar 16, 2026, 17:10Arturo Cesaro: First Meta-Analysis on the Vascular Protective Role of Semaglutide in PAD
-
Mar 16, 2026, 17:01Jeff Sternlicht: The Most Powerful Time to Lower Cholesterol Is Before Anyone Thinks You Need It
-
Mar 16, 2026, 16:14Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk